United Therapeutics Corp Form 4 Filings

UNITED THERAPEUTICS Corp (UTHR) reported that Chairperson & CEO Martine A. Rothblatt, through family trusts, exercised 9,500 stock options on September 15, 2026 at an exercise price of $117.76 per share and acquired an equal number of common shares. The trusts then sold 9,500 common shares in multiple open-market transactions at weighted average prices around $500–$505 per share, all pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025. Following the option exercise, family trusts report holding 432,910 stock options from the same grant, while Rothblatt also reports 40,513 UTHR shares held directly and 166 shares held indirectly by spouse.

UNITED THERAPEUTICS Corp (UTHR) reported that Chairperson & CEO Martine A. Rothblatt, through family trusts, exercised 9,500 stock options at an exercise price of $117.76 per share on September 14, 2026, receiving 9,500 common shares and then selling those 9,500 shares in multiple open-market trades around $502–$506 per share. The option exercise and related sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, and 442,410 options of this grant remain held by a family trust after the exercise.

UNITED THERAPEUTICS Corp (UTHR) director Nilda Mesa exercised stock options for 130 shares of common stock on September 14, 2026 at an exercise price of $110.86 per share, then sold a total of 228 shares in two transactions at prices around $505.8 per share. Following the option exercise, she held 6,430 stock options directly, and no transactions were reported under a Rule 10b5-1 trading plan.

UNITED THERAPEUTICS Corp (UTHR) reported that Chairperson & CEO Martine A. Rothblatt, through a family trust, exercised 9,500 stock options for common stock at $117.76 per share and on September 11, 2026 sold 9,500 common shares in multiple trades at prices around $497–$508 per share. After the exercise, the trust held 451,910 stock options, while separate holding entries show 40,513 shares held directly and 166 shares held indirectly by spouse. The option exercise and related sales were made under a pre‑arranged Rule 10b5‑1 trading plan adopted on November 7, 2025, which is scheduled to continue until the earlier of the exercise of 1,734,410 options expiring March 15, 2027 or December 31, 2026.

UNITED THERAPEUTICS Corp (UTHR) Chairperson & CEO Martine A. Rothblatt, through family trusts, exercised 9,500 stock options for common stock at an exercise price of $117.76 per share on September 10, 2026, and sold the resulting 9,500 common shares in multiple trades around $498–$509 per share.

The option exercise and related sales were made under a Rule 10b5-1 trading plan adopted on November 7, 2025. After the exercise, a family trust held 461,410 stock options expiring March 15, 2027, and Rothblatt also reported 40,513 common shares held directly and 166 shares held indirectly by spouse.

UNITED THERAPEUTICS Corp (UTHR) reported that Chairperson & CEO Martine Rothblatt, through family trusts, exercised 9,500 stock options for common stock at an exercise price of $117.76 per share on September 9, 2026, and the resulting 9,500 shares were sold in multiple open-market transactions at prices generally around $494–$509 per share.

The option exercise was from a grant expiring March 15, 2027, leaving 470,910 options held indirectly by a trust after the transaction. The trades were executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025. Rothblatt also reports 40,513 shares held directly and 166 shares held indirectly by a spouse, in addition to other trust holdings.

UNITED THERAPEUTICS Corp (UTHR) reports that Chairperson & CEO Martine A. Rothblatt, through a family trust, exercised 9,500 stock options for common stock at an exercise price of $117.76 per share on September 8, 2026, and the trust sold 9,500 common shares in multiple trades on the same date.

The filing states these transactions were made pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, and that 480,410 stock options expiring March 15, 2027 remain held indirectly by a family trust after this exercise.

UNITED THERAPEUTICS Corp (UTHR) reported that Chairperson & CEO Martine Rothblatt, through a family trust, exercised 9,500 stock options on September 4, 2026 at an exercise price of $117.76 per share and received 9,500 shares of common stock. The trust then sold 9,500 common shares the same day in multiple open-market transactions at weighted average prices between roughly $485 and $492 per share under a pre-arranged Rule 10b5-1 trading plan adopted November 7, 2025. Following the option exercise, the family trust continues to hold 489,910 stock options expiring March 15, 2027, and Rothblatt also has 40,513 common shares held directly and 166 shares held indirectly by a spouse.

UNITED THERAPEUTICS Corp (UTHR) reported that Chairperson & CEO Martine A. Rothblatt, through family trusts, exercised stock options for 9,500 shares of common stock on September 3, 2026, at strike prices of $135.42 and $117.76 per share and sold 9,500 shares in multiple trades at prices ranging from about $478.44 to $491.55. These transactions were made pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which may continue until the earlier of the exercise of 1,734,410 stock options expiring March 15, 2027, or December 31, 2026. Following these transactions, Rothblatt is reported as holding 40,513 shares directly and 166 shares indirectly through a spouse, with additional holdings and options in family trusts where she and/or her spouse share investment power.

UNITED THERAPEUTICS Corp (UTHR) executive Paul A. Mahon, EVP & General Counsel, reported exercising stock options for 8,300 shares of common stock on September 3, 2026 at an exercise price of $146.03 per share and selling the resulting 8,300 shares in a series of trades on the same date. The filing states these option exercises and share sales were made pursuant to a pre-arranged Rule 10b5-1 trading plan entered into on August 11, 2025. Following the exercise, Mahon continues to hold 55,840 stock options directly.

UNITED THERAPEUTICS Corp (UTHR) disclosed that family trusts associated with Chairperson & CEO Martine A. Rothblatt exercised 9,500 stock options at an exercise price of $135.42 per share on September 2, 2026, acquiring 9,500 common shares indirectly and selling 9,500 common shares in multiple transactions around $478–$510 per share.

The option exercise and related sales were made pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025. After this exercise, the relevant family trust held 8,910 stock options, while Rothblatt also held 40,513 common shares directly and 166 shares indirectly through a spouse.

For UNITED THERAPEUTICS Corp (UTHR), Chairperson & CEO Martine A. Rothblatt reported an exercise of 9,500 stock options at an exercise price of $135.42 per share on September 1, 2026, held indirectly through a family trust. The options converted into 9,500 shares of common stock, which were then sold indirectly by the trust in a series of open-market transactions totaling 9,500 shares at weighted average prices ranging from about $510.43 to $516.57 per share. After the option exercise, the trust reported holding 18,410 stock options of the same series. The filing also lists 40,513 shares of common stock held directly, and 166 shares held indirectly by a spouse. All option exercises and related sales were made pursuant to a Rule 10b5-1 trading plan adopted on November 7, 2025, which continues until the earlier of the exercise of 1,734,410 options expiring March 15, 2027, or December 31, 2026.

UNITED THERAPEUTICS Corp (UTHR) reports that Chairperson & CEO Martine A. Rothblatt, through family trusts, exercised 9,500 stock options at an exercise price of $135.42 per share into 9,500 shares of common stock on August 31, 2026. The same day, those 9,500 shares were sold in multiple trades at weighted average prices around $508–$515 per share, under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025. After this option exercise, a family trust holds 27,910 stock options, while Rothblatt also reports 40,513 shares of common stock held directly and 166 shares held indirectly by spouse.

UNITED THERAPEUTICS Corp (UTHR) reported that Chairperson & CEO Martine A. Rothblatt, through a family trust, exercised stock options for 9,500 shares of common stock at an exercise price of $135.42 per share on August 28, 2026. The resulting 9,500 shares of common stock were then sold in multiple open-market transactions at weighted-average prices generally between about $514 and $524 per share, each trade executed in multiple lots within specified price ranges. These transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which contemplates the potential exercise of up to 1,734,410 stock options expiring March 15, 2027, or earlier termination on December 31, 2026. Following these transactions, reported holdings include 40,513 shares of common stock held directly, 166 shares held indirectly by a spouse, and 37,410 stock options held in a family trust, with additional shares and options held through various family trusts where the reporting person and immediate family members are beneficiaries.

UNITED THERAPEUTICS Corp (UTHR) reported insider activity by Chairperson & CEO Martine A. Rothblatt through family trusts. On 2026-08-27, a trust exercised 9,500 stock options at an exercise price of $135.42 per share into an equal number of common shares, then sold 9,500 common shares in multiple open-market transactions at weighted-average prices generally between about $511 and $531 per share. The option exercise and related sales were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025. Following these transactions, a family trust continued to hold 46,910 stock options with a $135.42 exercise price, while reported common stock holdings included 40,513 shares held directly and 166 shares held indirectly by a spouse, with additional indirect holdings through family trusts.

UNITED THERAPEUTICS Corp (UTHR) reported that Chairperson & CEO Martine A. Rothblatt, through family trusts, exercised 9,500 stock options for common stock at an exercise price of $135.42 per share and acquired an equal number of shares on August 26, 2026. Those 9,500 shares were then sold the same day in multiple open-market transactions by a family trust at weighted-average prices in the $514–$521 range, under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025. Following the option exercise, a family trust continued to hold 56,410 stock options expiring March 15, 2027, and separate entries show direct ownership of 40,513 UTHR shares and additional indirect holdings, including 166 shares held by a spouse.

UNITED THERAPEUTICS Corp (UTHR) reported that Chairperson & CEO Martine A. Rothblatt, through family trusts, exercised 9,500 stock options for common stock at an exercise price of $135.42 per share and acquired 9,500 common shares on August 25, 2026. The same day, those 9,500 indirectly held shares were sold in multiple open-market transactions at weighted average prices between $515.46 and $520.52 per share. After the option exercise, a family trust held 65,910 stock options, and separately, Rothblatt held 40,513 common shares directly and 166 shares indirectly through a spouse. These option exercises and related sales were made under a Rule 10b5-1 trading plan adopted on November 7, 2025, which continues until the earlier of the exercise of 1,734,410 stock options expiring March 15, 2027, or December 31, 2026.

UNITED THERAPEUTICS Corp (UTHR) reported that family trusts associated with Chairperson & CEO Martine A. Rothblatt exercised 9,500 stock options at an exercise price of $135.42 per share into common stock and sold 9,500 common shares on August 24, 2026 in multiple trades at weighted-average prices around $509–$513 per share. The options transaction reduced the trust’s stock option position to 75,410 options. These transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which continues until the earlier of the exercise of 1,734,410 options expiring March 15, 2027 or December 31, 2026. Separately, Rothblatt reports 40,513 UTHR common shares held directly and 166 shares held indirectly by spouse.

UNITED THERAPEUTICS Corp (UTHR) reported that Chairperson & CEO Martine A. Rothblatt, through family trusts, exercised 9,500 stock options at an exercise price of $135.42 per share and acquired 9,500 shares of common stock on August 21, 2026. On the same date, those 9,500 common shares were sold in multiple trades at weighted-average prices, with individual trades executed in ranges from $512.51 to $528.02 per share, under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025. Following the option exercise, a family trust held 84,910 stock options, while reported direct common stock holdings were 40,513 shares, with additional indirect holdings by spouse and family trusts.

UNITED THERAPEUTICS Corp (UTHR) reported that Chairperson & CEO Martine A. Rothblatt, through a family trust, exercised 9,500 stock options at $135.42 per share into common stock and sold 9,500 common shares on August 20, 2026 at weighted average prices around $518–$525. These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025. Following the option exercise, the trust holds 94,410 stock options from this grant, while Rothblatt also reports 40,513 common shares held directly and 166 shares held indirectly by spouse, with additional indirect holdings in family trusts.

UNITED THERAPEUTICS Corp (UTHR) reported that EVP & General Counsel Paul A. Mahon exercised stock options for 8,300 shares of common stock at an exercise price of $146.03 per share on August 20, 2026, and sold 8,300 shares in multiple open-market trades at prices between approximately $520.03 and $527.21. The options exercise and resulting share sales were carried out under a pre-arranged Rule 10b5-1 plan entered into on August 11, 2025.

UNITED THERAPEUTICS Corp (UTHR) reported that Chairperson & CEO Martine A. Rothblatt, through family trusts, exercised 9,500 stock options at an exercise price of $135.42 per share, receiving 9,500 shares of common stock, and on the same date sold 9,500 shares in multiple open-market transactions at prices around $522–$536 per share.

After the option exercise, a family trust held 103,910 stock options. Additional holdings reported include 40,513 shares held directly and 166 shares held indirectly by spouse. All option exercises and related sales were made under a Rule 10b5-1 trading plan adopted on November 7, 2025, which continues until the earlier of exercising 1,734,410 stock options expiring March 15, 2027, or December 31, 2026.

UNITED THERAPEUTICS Corp (UTHR) Chairperson & CEO Martine Rothblatt, through a family trust, exercised 9,500 stock options at an exercise price of $135.42 per share into 9,500 shares of common stock on August 18, 2026, then sold 9,500 shares in multiple open-market trades at weighted average prices around the low-$500s per share. After the option exercise, the family trust held 113,410 stock options, and Rothblatt also reported 40,513 shares held directly and 166 shares held indirectly by spouse. All option exercises and related sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which covers up to 1,734,410 options expiring March 15, 2027, or runs until December 31, 2026.

UNITED THERAPEUTICS Corp (UTHR) reported insider activity by Chairperson & CEO Martine A. Rothblatt involving option exercises and related sales executed through family trusts. A family trust exercised 9,500 stock options at an exercise price of $135.42 per share, converting them into 9,500 shares of common stock held indirectly.

On the same date, the trust sold a total of 9,500 common shares in multiple open-market transactions at weighted average prices ranging from about $501.06 to $508.17 per share. These trades were made under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which continues until the earlier of the exercise of 1,734,410 stock options expiring March 15, 2027, or December 31, 2026. Following the derivative transaction, a family trust continues to hold 122,910 stock options, while reported common stock holdings include 40,513 shares held directly by Rothblatt and 166 shares held indirectly by a spouse, plus additional indirect trust holdings.

UNITED THERAPEUTICS Corp’s Chairperson & CEO Martine A. Rothblatt, through family trusts, exercised 9,500 stock options at an exercise price of $135.42 per share into 9,500 shares of common stock, then sold 9,500 shares on August 14, 2026 in multiple open‑market trades at weighted‑average prices between about $494.61 and $501.14. The filing reports 132,410 stock options remaining in a family trust after this exercise, and direct holdings of 40,513 common shares plus 166 shares held indirectly by a spouse. These transactions were made under a pre‑arranged 10b5-1 trading plan adopted November 7, 2025, which continues until either the exercise of 1,734,410 options expiring March 15, 2027 or December 31, 2026.

UNITED THERAPEUTICS Chairperson & CEO Martine A. Rothblatt reported an option exercise and related stock sales for family trusts. On 2026-08-13, a family trust exercised 9,500 stock options at an exercise price of $135.42 per share, receiving 9,500 shares of common stock indirectly. The trust then sold 9,500 shares in multiple trades at weighted-average prices generally around $500–$513 per share. Following the option exercise, the trust continues to hold 141,910 stock options expiring on March 15, 2027. Separately, Rothblatt holds 40,513 shares directly and 166 shares indirectly through a spouse. The option exercise and sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which is scheduled to continue until the earlier of exercising 1,734,410 options expiring March 15, 2027 or December 31, 2026.

United Therapeutics Corp Chairperson & CEO Martine A. Rothblatt, through a family trust, exercised 9,500 stock options at an exercise price of $135.42 and acquired an equal number of common shares on 2026-08-12. The trust then sold 9,500 common shares in multiple trades at weighted-average prices around $507–$521 per share pursuant to a pre-arranged Rule 10b5-1 trading plan. After the option exercise, the family trust held 151,410 stock options with a March 15, 2027 expiration, while Rothblatt also reported 40,513 directly held common shares and 166 shares held indirectly by a spouse.

United Therapeutics Corp Chairperson & CEO Martine A. Rothblatt, through a family trust, exercised 9,500 stock options at an exercise price of $135.42 per share into common stock on 2026-08-11, then sold 9,500 common shares in multiple trades at prices reported between roughly $512.94 and $531.29 per share. The option exercise and related sales were made pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which covers up to 1,734,410 stock options expiring March 15, 2027 and is scheduled to continue until the earlier of that full exercise or December 31, 2026. Following the option transaction, a family trust associated with the reporting person held 160,910 stock options, and reported direct common stock holdings were 40,513 shares, with an additional 166 shares held indirectly by spouse and further shares held in various family trusts.

UNITED THERAPEUTICS Corp Chairperson & CEO Martine A. Rothblatt, through family trusts, exercised 9,500 stock options at an exercise price of $135.42 per share on August 10, 2026, acquiring 9,500 shares of common stock. On the same date, those 9,500 common shares were sold in multiple open-market transactions at prices generally in the $523–$539 per-share range. Following the option exercise, the trust continues to hold 170,410 stock options with an expiration date of March 15, 2027. The activity was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which remains in effect until the earlier of the exercise of 1,734,410 stock options expiring March 15, 2027, or December 31, 2026. Separately, Rothblatt reports direct ownership of 40,513 common shares and indirect ownership of 166 common shares held by a spouse, with additional indirect holdings in family trusts.

United Therapeutics Corp Chairperson & CEO Martine A. Rothblatt, through a family trust, exercised 9,500 stock options into common stock at an exercise price of $135.42 per share and on August 7, 2026 sold 9,500 common shares in multiple transactions at per-share prices reported between roughly $525 and $540. The options transaction left 179,910 stock options held by the trust. These trades were made under a Rule 10b5-1 trading plan adopted on November 7, 2025, which continues until the earlier of the exercise of 1,734,410 stock options expiring March 15, 2027 or December 31, 2026. Reported holdings also include 40,513 shares held directly and 166 shares held indirectly by spouse.

United Therapeutics Chairperson & CEO Martine A. Rothblatt, through a family trust, exercised stock options for 9,500 shares at an exercise price of $135.42 on August 6, 2026, then sold the resulting 9,500 common shares in multiple indirect transactions at per-share prices including $512.5000 and $532.3932.

These option exercises and sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which will continue until the earlier of the exercise of 1,734,410 options expiring March 15, 2027 or December 31, 2026; 189,410 options remain held by the family trust, alongside direct and other indirect share holdings.

United Therapeutics Corp executive Paul A. Mahon exercised stock options for 8,300 shares of common stock at $146.03 per share, then sold 8,300 shares in several trades on August 6, 2026, at weighted‑average prices per share including $512.9174 and $521.4972. After the exercise he held 72,440 stock options. The transactions were executed under a pre‑arranged Rule 10b5‑1 trading plan entered into on August 11, 2025.

United Therapeutics Chairperson & CEO Martine A. Rothblatt, via a family trust, exercised 9,500 stock options at $135.42 per share into common stock and sold 9,500 shares in multiple trades on August 5, 2026. These transactions were made under a pre-arranged 10b5-1 trading plan adopted November 7, 2025, which contemplates exercising up to 1,734,410 options expiring March 15, 2027. Following this exercise, a family trust continues to hold 198,910 stock options, and Rothblatt also reports 40,513 common shares held directly, in addition to other indirect holdings through family trusts.

United Therapeutics chairperson and CEO Martine A. Rothblatt, indirectly through family trusts, exercised 9,500 stock options at $135.4200 per share on August 4, 2026 and received an equal number of common shares.

On the same date those 9,500 shares were sold in multiple tranches at reported weighted average prices such as $512.4859, $516.5935 and $517.4960 per share, under a pre-arranged Rule 10b5-1 trading plan adopted November 7, 2025.

The plan continues until the earlier of exercising up to 1,734,410 stock options expiring March 15, 2027 or December 31, 2026; 208,410 stock options remain held indirectly in a family trust, plus 40,513 shares held directly and 166 shares held indirectly by a spouse.

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics, through family trusts exercised 9,500 stock options at $135.42 and sold 9,500 shares of common stock on August 3, 2026 at weighted-average prices between $514.83 and $518.61, under a pre-arranged 10b5-1 trading plan adopted November 7, 2025. After the exercise, a family trust held 217,910 options expiring March 15, 2027, while Rothblatt held 40,513 shares directly and 166 shares indirectly via a spouse.

United Therapeutics Corp Chairperson & CEO Martine A. Rothblatt, through family trusts, exercised 9,500 stock options at $135.4200 per share on July 31, 2026, acquiring 9,500 common shares. The trusts then sold 9,500 shares that day in multiple reported transactions at weighted-average prices, all under a pre-arranged 10b5-1 trading plan adopted November 7, 2025. After the exercise, a family trust continued to hold 227,410 options, while Rothblatt also held 40,513 shares directly and 166 shares indirectly through her spouse, plus additional holdings in family trusts.

United Therapeutics Corp Chairperson & CEO Martine A. Rothblatt, through family trusts where she shares investment power, exercised 9,500 stock options at a strike price of $135.42 to acquire the same number of common shares, then sold 9,500 shares in several open-market or private transactions at weighted average prices in the low $520s per share. The option exercise and related sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which will continue until the earlier of exercising 1,734,410 stock options expiring March 15, 2027 or December 31, 2026.

United Therapeutics Chairperson & CEO Martine A. Rothblatt, through family trusts, exercised 9,500 stock options at an exercise price of $135.42 per share into common stock and, on July 29, 2026, sold the resulting 9,500 shares in multiple open-market transactions under a pre-arranged 10b5-1 trading plan adopted November 7, 2025.

After this exercise, a family trust reported holding 246,410 stock options expiring March 15, 2027, while Rothblatt also reported 40,513 shares held directly and 166 shares held indirectly through a spouse, along with additional share holdings in family trusts.

United Therapeutics Corp Chairperson & CEO Martine A. Rothblatt, through family trusts, exercised 9,500 stock options at $135.4200 per share and received 9,500 common shares, then sold 9,500 shares in multiple transactions on 2026-07-28. The trades were executed under a pre-arranged 10b5-1 trading plan adopted November 7, 2025 that covers up to 1,734,410 options expiring March 15, 2027. Following the exercise, a family trust holds 255,910 options, and Rothblatt reports 40,513 shares directly and 166 shares indirectly via her spouse, along with additional family-trust holdings.

United Therapeutics Chairperson & CEO Martine A. Rothblatt, through family trusts, exercised 9,500 stock options at $135.42 and acquired 9,500 common shares on July 27, 2026. Those shares were then sold in multiple trades totaling 9,500 shares at prices between about $526 and $535 per share under a pre-arranged Rule 10b5-1 plan adopted November 7, 2025. Following the exercise, a trust reports 265,410 options remaining, as part of up to 1,734,410 options covered by the plan and expiring March 15, 2027, while separate entries show 40,513 shares held directly and 166 shares held indirectly by spouse.

United Therapeutics Chairperson & CEO Martine A. Rothblatt reported that family trusts with which she shares investment power exercised 9,500 stock options at an exercise price of $135.42 per share and sold 9,500 shares of common stock on July 24, 2026 at weighted-average prices between approximately $528 and $535 per share, pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025.

Following the exercise, the trusts continue to hold 274,910 stock options from this grant expiring March 15, 2027, and Rothblatt also directly owns 40,513 common shares. The trading plan will continue until the earlier of the exercise of up to 1,734,410 stock options or December 31, 2026.

United Therapeutics Corp Chairperson & CEO Martine A. Rothblatt, through family trusts, exercised 9,500 stock options at $135.42 per share into common stock on 2026-07-23 and sold the resulting 9,500 shares in multiple transactions at prices between $522.31 and $531.94 per share.

The options, expiring March 15, 2027, are covered by a pre-arranged Rule 10b5-1 trading plan adopted November 7, 2025, which continues until the earlier of exercising 1,734,410 options or December 31, 2026. After this exercise, 284,410 options remain held indirectly by a family trust, and Rothblatt also holds 40,513 shares directly and 166 shares indirectly through a spouse.

United Therapeutics Corporation director Victor J. Dzau reported equity awards received on July 22, 2026 in connection with his appointment to the Board. He was granted 730 restricted stock units and 2,300 stock options under the Non-Employee Director Compensation Program. Each RSU represents one share of common stock upon vesting. The stock options cover common stock at an exercise price of $527.0700 per share, vest on the one-year anniversary of the grant date, and expire on July 22, 2033.

United Therapeutics granted director Linda Maxwell annual non-employee director equity awards on 2026-07-22, consisting of 380 restricted stock units and 1,190 stock options on common stock. The options carry a $527.0700 exercise price and expire on 2033-07-22.

Each restricted stock unit represents one share of common stock after vesting and has no expiration date. Both awards become fully vested on the earlier of one year from grant or the anticipated June 25, 2027 Annual Meeting of Shareholders. No sales or dispositions were reported.

United Therapeutics Corporation director Tommy G Thompson received equity compensation on July 22, 2026, consisting of 380 restricted stock units and 1,190 stock options with an exercise price of $527.07 per share.

The awards, described as an annual non-employee director grant, vest on the earlier of the one-year anniversary of the grant or the next Annual Meeting of Shareholders, with June 25, 2027 noted as the anticipated meeting date. Each restricted stock unit represents the right to receive one share of common stock after vesting and has no expiration date.

After these awards, Thompson holds 8,480 United Therapeutics common shares directly (including 880 issued from previously deferred RSUs), plus 8,200 shares held indirectly by a trust and 5,800 shares held indirectly through a family LLC.

Tracey Kevin reported acquisition or exercise transactions in this Form 4 filing.

United Therapeutics Corporation director Kevin Tracey reported an annual non-employee director equity award of 760 restricted stock units (RSUs) on July 22, 2026. Each RSU represents the right to receive, following vesting, one share of United Therapeutics common stock.

The RSUs become fully vested on the earlier of the one-year anniversary of the grant or the next Annual Meeting of Shareholders, anticipated on June 25, 2027. Following this grant, Tracey directly holds 760 RSUs, and the units have no stated expiration date.

Olian Judy D. reported acquisition or exercise transactions in this Form 4 filing.

United Therapeutics Corporation director Judy D. Olian received an annual non-employee director equity award of 760 restricted stock units (RSUs) on July 22, 2026. Each RSU entitles her to one share of common stock after vesting, with full vesting on the earlier of the one-year anniversary of grant or the next Annual Meeting of Shareholders, anticipated on June 25, 2027. Following this award, she holds 760 RSUs and 5,555 shares of common stock directly. The RSUs have no expiration date.

United Therapeutics director Jan Malcolm received equity compensation grants. On July 22, 2026, Malcolm was granted 380 restricted stock units and stock options for 1,190 shares of common stock at an exercise price of $527.07, as annual non-employee director awards. These awards vest on the earlier of the one-year anniversary of the grant date or the next Annual Meeting of Shareholders, anticipated on June 25, 2027. Following the grants, Malcolm directly holds 380 RSUs, 3,570 stock options and 450 common shares. The awards were reported as made pursuant to a Rule 10b5-1 trading arrangement.

United Therapeutics Corporation director Nilda Mesa received annual non-employee director equity awards on July 22, 2026, consisting of 380 restricted stock units and 1,190 stock options. Each restricted stock unit represents the right to receive one common share upon vesting. The options carry a $527.0700 exercise price and, together with the RSUs, are scheduled to become fully vested on the earlier of the one-year anniversary of the grant date or the next Annual Meeting of Shareholders, anticipated for June 25, 2027. After these awards, Mesa directly holds 5,678 shares of United Therapeutics common stock.